Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

AML Arising From Antecedent Hematologic Disorder (AHD): early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

AML Arising From Antecedent Hematologic Disorder (AHD): 1 US clinical trial tracked, none currently recruiting.

AML Arising From Antecedent Hematologic Disorder (AHD) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Institut de Recherches Internationales Servier, running 1 of these trials.

Enrollment posture brief

Registry condition aml-arising-from-antecedent-hematologic-disorder-ahd

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%AML Arising From Anteced (th…0%
Open-enrollment share among volume-matched conditions near AML Arising From Antecedent Hematologic Disorder (AHD)

AML Arising From Antecedent Hematologic Disorder (AHD) has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for AML Arising From Antecedent Hematologic Disorder (AHD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. AML Arising From Antecedent Hematologic Disorder (AHD) is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on AML Arising From Antecedent Hematologic Disorder (AHD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

idarubicin Drug
1 trials
daunorubicin Drug
1 trials
cytarabine Drug
1 trials
AG-221 Drug
1 trials
AG-120 Drug
1 trials

US sites by state

Facility locations filed on AML Arising From Antecedent Hematologic Disorder (AHD) trials. A trial with sites in several states counts in each.

Texas 1 trials
Tennessee 1 trials
South Carolina 1 trials
Ohio 1 trials
New York 1 trials
New Jersey 1 trials
Maryland 1 trials
Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this AML Arising From Antecedent Hematologic Disorder (AHD) page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No AML Arising From Antecedent Hematologic Disorder (AHD) trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Institut de Recherches Internationales Servier sponsors the most AML Arising From Antecedent Hematologic Disorder (AHD) trials on record, review their full trial history before evaluating a specific study. See Institut de Recherches Internationales Servier's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This AML Arising From Antecedent Hematologic Disorder (AHD) condition card totals 1 registered trials; most-linked intervention idarubicin; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.